The biotech industry tends to be highly volatile, because of the hit-and-miss nature of the products they are developing. Moderna is a recent example, having grown from a $4 billion company to a $59 billion company thanks in large part to the pandemic and the successful rollout of its coronavirus vaccine. As investors look for the next biotech hitmaker, they might want to take a closer look at two under-the-radar biotech firms that have some outstanding products up their sleeves.